Andreas Bernkop-Schnürch
University of Innsbruck, Austria

Prof. Andreas Bernkop-Schnürch was educated in pharmacy at the Institute of Pharmacy (M.Sc.) and in microbiology and genetics at the Institute of Microbiology and Genetics (D.Sc.), University of Vienna, finishing his doctorate in 1994. In 2003 he was appointed to a chair in pharmaceutical technology at the University of Innsbruck, Austria. From 2006 to 2013 he served as dean of the Faculty of Chemistry and Pharmacy at the University of Innsbruck. His research interest is in the area of mucoadhesive polymers, nanocarriers, peptide drug delivery and self-emulsifying drug delivery systems (SEDDS). He developed thiolated polymers (thiomers) and zeta-potential changing nanocarrier systems. Dr. Bernkop-Schnürch is author of over 370 research articles and reviews as well as editor and (co-)author of several books. He is the founder of Mucobiomer GmbH (now part of the Croma-Pharma Holding), Thiomatrix GmbH and Green River Polymers GmbH.
Presentation title: Oral peptide drug delivery: What intestinal barriers fear the most

Andreas Zimmer
Karl-Franz University of Graz, Austria

Prof. Andreas Zimmer (1963) studied Pharmacy at the Johann Wolfgang Goethe-University Frankfurt am Main, Germany. He stayed with a PhD program and did part of the work which focused on the evaluation of nanoparticles as ophthalmic drug delivery systems at the University of Wisconsin with Joe Robinson, Madison WI, USA. After the PhD at Jörg Kreuter’s lab in Frankfurt he continued with a university career at the Biocenter at the University of Frankfurt in the field of drug delivery and pharmaceutical nanotechnology. 1999 he joined the group of Robert Gurny in Geneva, Switzerland, as guest scientist and from 2000 on he moved to the University of Graz, first as guest lecturer and later as full professor. Since 2004 he is leading the Department of Pharmaceutical Technology and Biopharmacy at the Karl-Franzens-University in Graz, Austria. His research is focused on drug delivery and drug targeting devices and specialized on nanoparticles used for DNA- and RNA-drugs as well as for peptides and proteins.
Presentation title: Drug Delivery of micro-RNA

Chris Vervaet
Gent University, Belgium

Prof. Chris Vervaet is head of the Laboratory of Pharmaceutical Technology (Faculty of Pharmaceutical Sciences, Ghent University, Belgium), a research group focusing on the development and characterization of pharmaceutical solid dosage forms (granules, tablets, pellets, sustained release matrices). Over the last 10 years continuous manufacturing of solid dosage forms has been the one of main research topics of the team of Prof. Vervaet, focusing on processes such hot-melt extrusion, injection molding, wet granulation, tableting and blending. By evaluating the impact of formulation and process parameters on the performance of these continuous processes key information was obtained to smoothen the transition within the pharmaceutical industry from batch processing to continuous manufacturing. By combining the expertise of the Laboratory of Pharmaceutical Technology with the implementation of PAT tools during continuous manufacturing (in collaboration with Prof. De Beer, Laboratory of Pharmaceutical Process Analytical Technology, Ghent University) a better insight into the fundamental material behavior during continuous manufacturing was gained. This has resulted in multiple international collaborations, at an academic level as well as with large and small pharmaceutical companies. About 100 research papers have been published by the research group of Prof. Vervaet on the topic of continuous manufacturing of pharmaceuticals.
Presentation title: Continuous processing of solid dosage forms

György Németh, MD, PhD
Chief Medical Officer, Gedeon Richter Plc.
President of Hungarian Personalized Medicine Society

György Németh has been the Chief Medical Officer for Gedeon Richter Plc. since 2002. He is responsible for leading Gedeon Richter’s Medical Division, which includes chairing global clinical research, development and strategy teams; managing medical-regulatory- marketing issues and supervising pharmocovigilance activities.
He began his carrier at the Medical School of Debrecen University, Department of Neurology and Psychiatry. Later on, he worked as a fellow of Alexander von Humboldt Foundation at the Department of Pathochemistry and General Neurochemistry, University of Heidelberg , Germany. Afterwards he had different fellowships at the Karolinska Institute in Stockholm, Sweden and at New York University Medical Center in New York, USA at the same time. He continued his professional career as a clinical researcher at Knoll AG, Department of CNS R&D, where later, he took over the responsibility as Global Strategic Director for world-wide clinical and regulatory activities, launching among others two new chemical entities. His main activities were international leader in the clinical development of drug candidates for the treatment of stroke; Parkinson’s disease, epilepsy, major depression, schizophrenia, obesity and other non-CNS indications. One of the success stories under his clinical leadership at Gedeon Richter was that a pioneering antipsychoticum (cariprazine) was approved by the FDA. In the meantime, he succeeded in verifying the efficiency of cariprazine in a niche indication (predominantly negative symptoms of schizophrenia) which was previously lacking therapeutic possibilities. Thus, he instituted and led the clinical developments of a first-in-class drug by using stratification approach. Owing to his comprehensive science operation, he is an active member of umpteen societies including Hungarian, European and American societies. He is committed to personalized medicine.
He has been the President of Hungarian Personalized Medicine Society since its foundation (2010).
Presentation title: The Changing Landscape of Personal Medicine

Jörg Breitkreutz
Heinrich Heine University, Düsseldorf, Germany

Jörg Breitkreutz studied Pharmacy from 1987 to 1991 at the Westphalian Wilhelms-University of Münster, Germany. He finished his PhD in 1996 at the Institute for Pharmaceutical Technology and Biopharmaceutics in Münster under supervision of Prof. Rüdiger Gröning. From 1996 to 1997 he joined Thiemann Arzneimittel GmbH in Waltrop, Germany, as the head of Product Coordination. In 1997 he went back to the university in Münster to work on his habilitation thesis (2004) on pediatric drug formulations. In 2004 he became professor for pharmaceutical technology at the Institute of Pharmaceutics and Biopharmaceutics at the Heinrich-Heine-University in Düsseldorf, Germany, and today is the director of this institute. Joerg Breitkreutz serves as external expert for various regulatory bodies and companies. He is presently heading the Paediatric Formulation group at the European Directorate for the Quality of Medicines and Healthcare (EDQM). Since 2010 he is president of the non-for-profit International Association of Pharmaceutical Technology (APV). His research focuses on pediatric and geriatric drug formulations, drug printing technologies, orphan drugs, process analytical technologies, green and sustainable medicinal products.
Presentation title: Drug formulations for paediatric and geriatric patients

Niklas Sandler
Åbo Akademi University, Turku, Finland

Prof. Niklas Sandler received his M.Sc. (Pharm.) in 1998 from University of Helsinki, Finland. He got his Ph.D. in pharmaceutical technology from the University of Helsinki 2003. He was lecturer at the Pharmaceutical Technology Division, Helsinki between 2003-2005 and in 2005-2006 he was a postdoctoral researcher at the University of Otago, New Zealand, focusing on research on solid-state characterization of drugs. He became an adjunct professor in Pharmaceutical Technology at the University of Helsinki in 2007. Between 2006 and 2008 he had a senior researcher position at AstraZeneca, Pharmaceutical and Analytical R&D in the UK. From September 2008 until July 2009 was a temporary professor in Industrial Pharmacy at the University of Helsinki. Since August 2009 he has been full professor in Pharmaceutics at Åbo Akademi University (ÅAU), Turku, Finland and heads the research group in drug-delivery and pharmaceutical technology. He has pioneered in research around printable drug-delivery systems. The current aim of his research group is to increase the understanding of material behaviour in fabrication of printed drug-delivery systems and to explore various printing techniques in drug manufacture. He is the president of the Finnish Pharmaceutical Society since 2012. Vice rector responsible for research affairs and innovations of Åbo Akademi University since 2015. He is the president of the Finnish Pharmaceutical Society since 2012. He has been an Executive Board Member of EUFEPS from 2013 onwards.
Presentation title: Are printing technologies completely changing drug manufacturing of the future?

Odon Planinšek,
University of Ljubljana, Slovenia

Prof. Odon Planinšek has finished his studies as pharmacist (M.Sc) at the Faculty of Pharmacy, University of Ljubljana in 1996. He recieved PhD degree in 1999 on the same University. He is working in the Department of Pharmaceutical Technology since 1994. He became assistant professor in 2001, associate professor in 2006 and since 2012 he is a full pofessor of the Department of Pharmaceutical Technology. In 2001 and 2002 he performed postdoctoral studies in University of London, Faculty of Pharmacy. He is a member of the Slovenian Pharmaceutical Society and between 2005 and 2015 he served as associate editor of the Acta Pharmaceutica journal. His main research interest is preformulation, deformulation and formulation of solid paricles and tablets.
Presentation title: Particles design and solid dosage forms

Piroska Szabó-Révész
University of Szeged, Hungary

Prof. Piroska Szabó-Révész has got her diploma as pharmacist in Albert Szent-Györgyi Medical University of Szeged in 1975. She has got her university doctorate in the same University in 1979 and in the same year she became a specialist pharmacist in pharmaceutical technology. She has got her PhD degree in Semmeweis University, Budapest in 1992. She has done her habilitation in Albert Szent Györgyi Medical University of Szeged in 1996. She became the Doctor of Sciences (D.Sc.) in 2006. She was nominated as full professor in 2004 and served as the Head of the Department of Pharmaceutical Technology, University of Szeged between 2005 and 2016. She is the Head of Pharmaceutical Technological Program at the PhD School for Pharmaceutics and Chair of the Habilitation Committee of the Pharmaceutical Sciences in University of Szeged. She is the Head of the Nanotechnological research team at the Institute of Pharmaceutical Technology and Regulatory Affairs. She was the supervisior of 16 PhD thesis and 25 diploma works. She is doing reviewing activity for 10 journals. She is the leader of numerous national and international projects. She has given 130 lectures at national and international scientific events, participated in more than 60 industrial research-development projects, was the author of 3 books, 10 book chapters, 3 university hand-outs, 221 papers and 2 patents Her main fields of interest are particle engineering, micronization, nanonization and amorphization of crystalline pharmaceutical agents, solid-phase analysis, development of drug delivery systems for nasal and pulmonary administration.
Presentation title: Modifying the physicochemical properties of NSAIDs for nasal administration

Tamás L. Paál
National Institute of Pharmacy and Nutrition and University of Szeged, Hungary

Prof. Tamás L. Paál graduated in Pharmacy, postgraduated in drug control and chemical engineering then received his Ph.D. at different Universities, all in Budapest. Having worked 11 years for the Hungarian pharmaceutical industry he joined the National Institute of Pharmacy, the Hungarian medicines regulatory authority in 1978. He was Director-General of the Institute between 1984 and 2008. Having been retired he has been scientific adviser of the agency (now National Institute of Pharmacy and Nutrition). He has been promoted Professor in 1984. He has worked in the Postgraduate Medical University then the Semmelweis University, Budapest until his retirement in 2013. Parallelly he was invited to create the Institute of Drug Regulatory Affairs at the Faculty of Pharmacy, University of Szeged and directed this between 2002 and 2008. He became Professor emeritus (at present at the Institute of Pharmaceutical Technology and Regulatory Affairs) in 2013. He worked on different regulatory missions for UNIDO, WHO and the EU PHARE Project in Central America, Central Asia, Africa and Eastern Europe. He received, among others, the Life-long membership award from TOPRA (The Organisation of Professionals in Regulatory Affairs) and was awarded also by DIA (Drug information Association) and RAPS (the Regulatory Affairs Professionals Society). He is member of the European Academy of Sciences and Arts.
He published 230 papers, mainly on chemistry and regulatory affairs.